Phar­ma com­pa­nies tone down ESG men­tions, but not am­bi­tions

Phar­ma com­pa­nies are scal­ing back the use of terms like “ESG” and “di­ver­si­ty, eq­ui­ty and in­clu­sion,” much like com­pa­nies in oth­er in­dus­tries.

In phar­ma 10-K fil­ings, men­tions of ESG, sus­tain­abil­i­ty, or di­ver­si­ty, eq­ui­ty and in­clu­sion (DE&I) dropped 15% in the first quar­ter of the year, com­pared to the same three months in 2023, ac­cord­ing to da­ta from Al­phaSense. Of the phar­ma an­nu­al fil­ings in the first three months of 2024, 65 men­tioned any of those terms, down from 76 dur­ing the same pe­ri­od last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER